Table 4:

Results of Previous Studies Addressing SATB2 Expression in Neuroendocrine Neoplasms

	Dragomir et al (2014)(18)	Lin et al (2014)(23)	Li et al (2015)(21)	Fukuhara et al (2016)(22)	Kervarrec et al (2018)(26)
Clone	CL0276	SATBA4B10 and EP281/EPNCIR130B	EPNCIR130A	CL0320	Not specified
NET	“Carcinoid” (n=54): 0–1%: 59% 2–25%: 22% 26–75%: 2% >75%: 13%	Medullary carcinoma (n=12): 0% Unpublished observation that SATB2 expressed by “majority of NETs of the colon, rectum, and appendix but rarely in NETs from the stomach, duodenum, small intestine, pancreas, and lung”	Foregut (n=84): 17% Midgut (n=25): 12% Hindgut (n=58): 90%	“Carcinoid” (n=10): 0%	Not examined
Pheochromocytoma/paraganglioma	Not reported	Pheochromocytoma (n=13): 0%	Not examined	Not examined	Not examined
NEC	3 Merkel cell carcinomas showed staining in >75% of nuclei	Not examined	Unpublished observation that SATB2 is expressed by “one third of PDNECs of various organs”	Merkel cell (n=20): 75% Small cell lung (n=4): 0%	Merkel cell (n=98): High expressors:64% Low Expressors: 24% Negative: 12% Visceral (n=57): High expressors: 2% Low expressors: 18% Negative: 80%